|Table of Contents|

Clinical characteristics,treatment,and prognosis analysis of high-grade B-cell lymphoma(67 cases)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4586-4590
Research Field:
Publishing date:

Info

Title:
Clinical characteristics,treatment,and prognosis analysis of high-grade B-cell lymphoma(67 cases)
Author(s):
LI Jiayin1; ZHANG Mingzhi2; YAO Lige1
1.Department of Oncology,the Third People＇s Hospital of Zhengzhou,Henan Zhengzhou 450052,China;2.Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450052,China.
Keywords:
high-grade B-cell lymphoma; clinical characteristics; treatment; prognosis
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.24.019
Abstract:
Objective:Comparative analysis of clinical characteristics,treatment and prognosis of the two types of high-grade B-cell lymphoma(HGBL).Methods:The clinical data of 67 patients with HGBL(including HGBL,R and HGBL,NOS) from January 2013 to June 2022 were analyzed retrospectively.The clinical characteristics,treatment and prognosis of patients with two types of HGBL were compared and analyzed.Results:Among 67 patients，39 cases (58.2%) were determined as HGBL,R,and 28 cases (41.8%) were HGBL,NOS.Bone marrow infiltration,extranodal disease,in the advanced clinical stage,high IPI (international prognostic index) score and elevated LDH level are more likely to occur in HGBL,R group（P＜0.05).Prognostic analysis showed that overall survival (OS) time and progression-free survival (PFS) in HGBL,R group were significantly shorter than those in HGBL,NOS group (all P＜0.05)．Further analysis demonstrated that the patients with HGBL who received high-intensity chemotherapy regimens had longer PFS and OS（OS：χ2=8.194，P=0.004；PFS:χ2=9.006，P=0.002).Multivariate analysis showed that high-intensity chemotherapy regimens were independent risk factors for PFS and OS（P＜0.05).Conclusion:HGBL,R patients have worse prognosis than HGBL,NOS patients,and high-intensity chemotherapy（DA-EPOCH-R，R-CODOX-M/IVAC or R-HyperCVAD） may improve the patients' prognosis.

References:

［1］SWERDLOW SH,CAMPO E,PILERI SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］．Blood,2016,127(20):2375-2390.
［2］FALINI B,MARTINO G,LAZZI S.A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas［J］.Leukemia,2023,37(1):18-34.
［3］OLSZEWSKI AJ,KURT H,EVENS AM.Defining and treating high-grade B-cell lymphoma,NOS［J］.Blood,2022,140(9):943-954.
［4］CHESON BD,PFISTNER B,JUWEID ME,et al.Revised response criteria for malignant lymphoma［J］．Journal of Clinical Oncology,2007,25(5):579-586.
［5］CHESON BD,FISHER RI,BARRINGTON SF,et al.Recommendations for initial evaluation,staging,and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification［J］．Journal of Clinical Oncology,2014,32(27):3059-3068.
［6］KONG H,ZHU H,ZHENG X,et al.Machine learning models for the diagnosis and prognosis prediction of high-grade B-cell lymphoma［J］.Frontiers Immunology,2022,13:919012.
［7］KING RL,HSI ED,CHAN WC,et al.Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma［J］.Virchows Arch,2023,482(1):193-205.
［8］ALDERUCCIO JP,AI WZ,RADFORD J,et al.Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma:a subgroup analysis from the LOTIS-2 study［J］.Blood Advances，2022,6(16):4736-4739.
［9］LI S,QIU L,XU J,et al.High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL［J］.Leukemia,2023,37(2):422-432.
［10］李佳音,张明智.22例高级别B细胞淋巴瘤非特指型的临床分析［J］.肿瘤基础与临床,2020,33(02):132-138. LI JY,ZHANG MZ.Clinical analysis of 22 patients with high grade B-cell lymphomas-not otherwise specified［J］.Journal of Basic and Clinical Oncology,2020,33(02):132-138.
［11］SUN H,SAVAGE KJ,KARSAN A,et al.Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation［J］.Clinical Lymphoma,Myeloma and Leukemia,2015,15(6):341-348.
［12］LI JY,LIU XY,YAO ZH,et al.High-grade B-cell lymphomas,not otherwise specified:A study of 41 cases［J］.Cancer Management and Research,2020,12:1903-1912.
［13］LANDSBURG DJ,NASTA SD,GERSON JN,et al.Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy［J］.Leukemia Lymphoma,2022,63(1):243-246.
［14］CHEN AI,LEONARD JT,OKADA CY,et al.Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma［J］.Leukemia Lymphoma,2018,59(8):1884-1889.
［15］LAP CJ,NASSEREDDINE S,DUNLEAVY K.Novel biological insights and new developments in management of Burkitt lymphoma and high-grade B-cell lymphoma［J］.Current Treatment Options in Oncology,2021,22(7):60.
［16］THOMAS N,DREVAL K,GERHARD DS,et al.Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma［J］.Blood,2023,141(8):904-916.
［17］GRAEF CM,GODEL P,FALDERBAUM P,et al.Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma［J］.European Journal of Haematology,2022,108(5):403-412.
［18］KHANLARI M,MEDEIROS LJ,LIN P,et al.Blastoid high-grade B-cell lymphoma initially presenting in bone marrow:a diagnostic challenge［J］.Modern Pathology,2022,35(3):419-426.
［19］EVRARD SM,PRICART S,GRAND D,et al.Targeted next generation sequencing reveals high mutation frequency of CREBBP,BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements［J］.Haematologica,2019,104(4):e154-e157.
［20］CRAIG A,WEN KW.EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements［J］.Blood,2022,140(4):406.

Memo

Memo:
河南省医学科技攻关计划联合共建项目（编号：LHGJ20210732）
Last Update: 1900-01-01